BOLERO-2研究解读:依维莫司联合依西美坦在激素受体阳性进展性乳腺癌的临床实践依据  

The Interpretation of BOLERO-2 Trial: Clinical Application Analysis on Everolimus Plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer

作　　者：王先明[1] 肖瑜[1] 

机构地区：[1]深圳大学第一附属医院甲状腺乳腺外科,广东深圳518037

出　　处：《循证医学》2016年第3期145-148,共4页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Piccart M,Hortobagyi GN,Campone M,et al.Everolimus plus Exemestane for hormone receptorpositive,human epidermal growth factor receptor-2-negative advanced breast cancer：Overall survival results from BOLERO-2[J].Ann Oncol,2014,25（12）：2357-2362.<正>1文献来源Piccart M,Hortobagyi GN,Campone M,et al.Everolimus plus Exemestane for hormone receptorpositive,human epidermal growth factor receptor-2-negative advanced breast cancer:Overall survival results from BOLERO-2[J].Ann Oncol,2014,25(12):2357-2362.

关 键 词：激素受体阳性乳腺癌 BOLERO-2 依维莫司 依西美坦 总生存期 

分 类 号：R737.9[医药卫生—肿瘤]